Testing the safety of NRG5051
Researchers are studying this experimental medicine in healthy volunteers and people with Parkinson's or motor neurone disease.
Testing a treatment or activity · Study reference: 2025-523872-22-00
Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓
Open the official registry record ↗Follow this study
Looking for volunteers
- Start (planned)
- 2025-11-17
- Study finished (planned)
- 2026-11-03
Planned dates can move. A study finishing does not tell us when a paper will be published.
No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.
Changes we have recorded
- 2026-10-11 — recruiting
These are dates we observed a change, not necessarily the dates it happened.
Papers connected to this study
No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.
Who can join?
Age range not listed · Ask the team who can join
These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.
Read all the rules for taking part
Sex eligibility reported by registry: Not reported
Full study name & original research details
Official study title
Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS
Original description
Conditions reported: Parkinsons's Disease and amyotrophic lateral sclerosis (ALS)
Registry records for this study
Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.
- Clinical Trials Information System · 2025-523872-22-00 ↗ — Authorised; checked 2026-10-11
- Study type
- Interventional
- Interventions
- Not reported
- Phases
- Human Pharmacology (Phase I)- First administration to humans
- Sponsor
- Nrg Therapeutics Limited
- Start date reported by registry
- 2025-11-17 (estimated)
Registry updated: 2026-07-09 · Status last verified by the registry submitter: Not reported
Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.
Contact the research team
Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.
David Brocklebank · +443337723451 · clinicaltrials@nrgtherapeutics.com
Study locations
Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.
Centre for Human Drug Research
Leiden, Netherlands
RecruitingThe original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.